Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

317 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interaction between age and gender on survival outcomes in extramedullary multiple myeloma over the past two decades.
Bangolo AI, Fwelo P, Trivedi C, Sagireddy S, Aljanaahi H, Auda A, Mohamed M, Onyeka S, Fisher M, Thapa J, Tabucanon EJ, Georgiev L, Wishart A, Kumari S, Erikson C, Bangura M, Paddy O, Madhukar R, Gomez EL, Rathod J, Naria M, Hajal B, Awadhalla M, Siegel D, Parmar H, Biran N, Vesole DH, Phull P, Weissman S. Bangolo AI, et al. Among authors: parmar h. World J Clin Oncol. 2023 Apr 24;14(4):179-189. doi: 10.5306/wjco.v14.i4.179. World J Clin Oncol. 2023. PMID: 37124133 Free PMC article.
Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment-67 Patients Multicenter Analysis.
Charliński G, Steinhardt M, Rasche L, Gonzalez-Calle V, Peña C, Parmar H, Wiśniewska-Piąty K, Dávila Valls J, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Gozzetti A, Ciofini S, Gentile M, Zamagni E, Kurlapski M, Legieć W, Vesole DH, Jurczyszyn A. Charliński G, et al. Among authors: parmar h. Cancers (Basel). 2024 Apr 21;16(8):1592. doi: 10.3390/cancers16081592. Cancers (Basel). 2024. PMID: 38672674 Free PMC article.
Post-ASCT consolidation with elotuzumab, lenalidomide, and dexamethasone or elotuzumab, pomalidomide, and dexamethasone in high-risk and ultra-high-risk multiple myeloma: a retrospective single-center study.
Zolotov E, Kabat M, Parmar H, Anand P, Zenreich J, Aleman A, Phull P, Doucette K, Vesole DH, Siegel DS, Biran N. Zolotov E, et al. Among authors: parmar h. Leuk Lymphoma. 2024 Dec;65(13):2000-2008. doi: 10.1080/10428194.2024.2385501. Epub 2024 Jul 31. Leuk Lymphoma. 2024. PMID: 39082756
Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.
Varma G, Fogel L, Gordon B, Saldarriaga MM, Ahn J, Aleman A, Caro J, Rosenberg MC, Monge J, Parmar H, Kaminetzky D, Moskovits T, Siegel DS, Morgan GJ, Niesvizky R, Davies FE, Biran N. Varma G, et al. Among authors: parmar h. Leuk Lymphoma. 2025 Jan 5:1-10. doi: 10.1080/10428194.2024.2446617. Online ahead of print. Leuk Lymphoma. 2025. PMID: 39756041
317 results